---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-006178"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2023-02-13T23:59:59+00:00"
generated_at: "2026-06-19T16:06:19.322101+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Roivant Q3 net loss widens to $385M; VTAMA revenue $9.2M, RVT-3101 Phase 2b positive

## Summary
- Net loss of $384.9M ($0.49 per share) for Q3 FY2023, compared to net loss of $306.1M ($0.41) a year ago.
- VTAMA net product revenue $9.2M; nearly 100,000 prescriptions written by ~8,600 prescribers since launch; 57% of commercial lives covered.
- RVT-3101 Phase 2b TUSCANY-2: 31% clinical remission (p=0.01) and 40% endoscopic improvement (p=0.01) at expected Phase 3 dose; biomarker-positive patients achieved 40%/56% rates.
- Completed $230M upsized equity offering; pro forma cash $1.9B, extending runway into 2H 2025.
- Topline data expected from ADORING 1 (VTAMA in atopic dermatitis) in March 2023 and ADORING 2 in May 2023.

## SEC filing metadata
- accession: 0001140361-23-006178
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2023-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036123006178/0001140361-23-006178-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036123006178/brhc10048029_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-006178
- JSON: https://secwatch.observer/filing/0001140361-23-006178.json
- Plain text: https://secwatch.observer/filing/0001140361-23-006178.txt

## Key facts
- Earnings Releases
  Roivant Sciences Ltd. reported financial results for the third quarter ended December 31, 2022.
  - Period: the third quarter ended December 31, 2022
  - Result: reported results
  source text: On February 13, 2023, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000114036123006178/0001140361-23-006178-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.